BICX - BioCorRx Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0706
-0.0094 (-11.75%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.0800
Open0.0720
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0602 - 0.0795
52 Week Range0.0410 - 0.2820
Volume116,455
Avg. Volume201,066
Market Cap17.882M
Beta (3Y Monthly)3.25
PE Ratio (TTM)N/A
EPS (TTM)-0.0230
Earnings DateNov 14, 2018 - Nov 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Brady Granier, CEO, President, and Director of BioCorRx Inc. Provides Update and Outlook in a New Audio Interview with SmallCapVoice.com

    SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that a new audio interview with the Company is now available. Brady Granier called in to SmallCapVoice.com, Inc. to discuss the progress the Company has made in several key areas, the operational outlook for 2019, the launch of a new weight loss program and more. BioCorRx, Inc. issued a third quarter business update in November outlining where the Company stands with NIDA on their grant application process.

  • GlobeNewswire2 months ago

    BioCorRx Provides Business Update for the Third Quarter of 2018

    ANAHEIM, CA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx, Inc. (BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the third quarter ended September 30, 2018. Brady Granier, CEO, President, and Director of BioCorRx, Inc., stated, “We continue to work on the advancement of BICX102, a sustained release naltrexone implant for the treatment of opioid and alcohol use disorders. In early October, we received a Just-In-Time (JIT) request from NIDA on our grant application submitted in May of this year.

  • GlobeNewswire3 months ago

    BioCorRx Inc.’s CEO Talks NIDA Grant Update and a Promising New Product with Uptick Newswire’s Stock Day Podcast

    BioCorRx Inc. (OTCQB: BICX) (the "Company") is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc, Brady Granier talked with Stock Day’s Everett Jolly about exciting developments at the company. Jolly asked for a general explanation of what it is that BioCorRx Inc. does to help fight addiction.

  • GlobeNewswire3 months ago

    BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families

    ANAHEIM, CA, Oct. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company’s R&D subsidiary, BioCorRx Pharmaceuticals, has acquired a portfolio of six Therakine Biodelivery GmbH patent families that broadly cover sustained release delivery platforms for the local delivery of biologic and small molecule drugs. The portfolio includes issued patents and several pending patent applications which relate to BICX101, an injectable, sustained release naltrexone for the treatment of opioid and alcohol use disorders.

  • ACCESSWIRE10 months ago

    SeeThruEquity Issues Update on BioCorRx Inc. (OTCQB: BICX) and Increases Price Target to $0.44

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...